NasdaqGM - Nasdaq Real Time Price USD
Verrica Pharmaceuticals Inc. (VRCA)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 7:48 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.37 | -0.28 | -1.42 | -0.87 |
| Low Estimate | -0.41 | -0.3 | -1.45 | -0.98 |
| High Estimate | -0.33 | -0.24 | -1.36 | -0.75 |
| Year Ago EPS | -0.54 | -0.53 | -1.48 | -1.42 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 5.25M | 6.63M | 20.9M | 48.89M |
| Low Estimate | 3.2M | 4.3M | 16.6M | 23.1M |
| High Estimate | 7.11M | 9.07M | 25.14M | 70M |
| Year Ago Sales | 510k | 1.99M | 5.12M | 20.9M |
| Sales Growth (year/est) | 929.40% | 233.50% | 307.90% | 133.90% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.36 | -0.53 | -0.39 | -0.42 |
| EPS Actual | -0.54 | -0.53 | -0.44 | -0.37 |
| Difference | -0.18 | 0 | -0.05 | 0.05 |
| Surprise % | -50.00% | 0.00% | -12.80% | 11.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.37 | -0.28 | -1.42 | -0.87 |
| 7 Days Ago | -0.37 | -0.28 | -1.42 | -0.87 |
| 30 Days Ago | -0.38 | -0.31 | -1.46 | -1.09 |
| 60 Days Ago | -0.37 | -0.31 | -1.49 | -0.96 |
| 90 Days Ago | -0.34 | -0.3 | -1.47 | -0.96 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VRCA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 31.50% | -- | -- | 3.70% |
| Next Qtr. | 47.20% | -- | -- | 7.90% |
| Current Year | 4.10% | -- | -- | 2.50% |
| Next Year | 38.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -78.20% | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 10/4/2024 |
| Downgrade | Needham: Buy to Hold | 10/3/2024 |
| Downgrade | Brookline Capital: Buy to Hold | 10/2/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 8/15/2024 |
| Maintains | Needham: Buy to Buy | 8/15/2024 |
| Reiterates | Needham: Buy to Buy | 5/16/2024 |
Related Tickers
SCPH scPharmaceuticals Inc.
4.5300
+3.19%
SYRE Spyre Therapeutics, Inc.
32.76
0.00%
IMAB I-Mab
1.4800
-7.50%
TSHA Taysha Gene Therapies, Inc.
2.0600
+1.48%
VTYX Ventyx Biosciences, Inc.
2.5400
+3.67%
YMAB Y-mAbs Therapeutics, Inc.
14.45
+1.76%
SLRN Acelyrin, Inc.
6.20
-4.32%
SVRA Savara Inc.
3.7600
+3.01%
SEEL Seelos Therapeutics, Inc.
1.2800
0.00%
STTK Shattuck Labs, Inc.
1.3500
-2.17%